Skip to main content

Critical Care Reviews Newsletter

Newsletter 560  |  September 5th, 2022

Disseminating Evidence since 2009

Niklas Nielsen presents the TTM2 Trial at CCR22

Welcome to the 560th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are randomised controlled trials on preoperative restriction of sulfur‐containing amino acid intake for the prevention of acute kidney injury after cardiac surgery & discomfort improvement for critically ill patients using electronic relaxation devices; systematic reviews and meta analyses on thromboelastography-guided therapy in cirrhotic patients & the use of dexmedetomidine in patients with sepsis; and observational studies on extubation in neurocritical care patients & strategies for lung- and diaphragm-protective ventilation in acute hypoxemic respiratory failure.

There are also guidelines on infective endocarditis in people who inject drugs & lung ultrasound; narrative reviews on antifibrinolytics for traumatic brain injury & platelet transfusion for trauma resuscitation; an editorial on the nephrotoxicity of adding piperacillin–tazobactam to vancomycin; and commentaries on compartmentalisation of immune responses in critical illness & paediatric ventilator liberation; as well as correspondence on decision-making process during meetings on the limitation of life-sustaining support in French ICUs & intracranial pressure pulse morphology.

If you only have time to read one review article this week, try this one on acute colchicine poisoning.

CCR22

The latest video to be released from CCR22 is Niklas Nielsen's presentation of the TTM2 trial, which coincides with Jakub Fronczek's visual abstract on this landmark trial.

Support CCR

You can support Critical Care Reviews, from as little as the price of a cup of coffee per month or make a one-off donation. Our aim is to share science for the benefit of all - please join us in this mission.

I hope you find this newsletter useful.


Until next week

Rob